Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 9605253, 10 pages
http://dx.doi.org/10.1155/2016/9605253
Research Article

PGC-1α-Dependent Mitochondrial Adaptation Is Necessary to Sustain IL-2-Induced Activities in Human NK Cells

1Department of Biochemistry and Molecular Biology, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Sergio Livingstone 1007, Independencia, 8380492 Santiago, Chile
2Department of Biology, Faculty of Chemistry and Biology, University of Santiago of Chile, Avenida Libertador Bernardo O’Higgins 3363, 9170022 Santiago, Chile

Received 3 November 2015; Revised 2 February 2016; Accepted 24 May 2016

Academic Editor: Jagadeesh Bayry

Copyright © 2016 Dante Miranda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Biron, K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather, “Natural killer cells in antiviral defense: function and regulation by innate cytokines,” Annual Review of Immunology, vol. 17, pp. 189–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. J. S. Orange and Z. K. Ballas, “Natural killer cells in human health and disease,” Clinical Immunology, vol. 118, no. 1, pp. 1–10, 2006. View at Publisher · View at Google Scholar
  3. E. O. Long, H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan, “Controlling natural killer cell responses: integration of signals for activation and inhibition,” Annual Review of Immunology, vol. 31, no. 1, pp. 227–258, 2013. View at Publisher · View at Google Scholar
  4. E. M. Mace, P. Dongre, H. T. Hsu et al., “Cell biological steps and checkpoints in accessing NK cell cytotoxicity,” Immunology and Cell Biology, vol. 92, no. 3, pp. 245–255, 2014. View at Publisher · View at Google Scholar
  5. W. M. Yokoyama, S. Kim, and A. R. French, “The dynamic life of natural killer cells,” Annual Review of Immunology, vol. 22, pp. 405–429, 2004. View at Publisher · View at Google Scholar
  6. J. H. Phillips, B. T. Gemlo, W. W. Myers, A. A. Rayner, and L. L. Lanier, “In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy,” Journal of Clinical Oncology, vol. 5, no. 12, pp. 1933–1941, 1987. View at Google Scholar · View at Scopus
  7. J. D. Bonnema, K. A. Rivlin, A. T. Ting, R. A. Schoon, R. T. Abraham, and P. J. Leibson, “Cytokine-enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis,” The Journal of Immunology, vol. 152, no. 5, pp. 2098–2104, 1994. View at Google Scholar · View at Scopus
  8. M. Hagenaars, S. Zwaveling, P. J. K. Kuppen et al., “Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses,” International Journal of Cancer, vol. 78, no. 6, pp. 783–789, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Panelli, E. Wang, G. Phan et al., “Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration,” Genome Biology, vol. 3, no. 7, Article ID RESEARCH0035, 2002. View at Google Scholar · View at Scopus
  10. G. Trinchieri, M. Matsumoto-Kobayashi, S. C. Clark, J. Seehra, L. London, and B. Perussia, “Response of resting human peripheral blood natural killer cells to interleukin 2,” The Journal of Experimental Medicine, vol. 160, no. 4, pp. 1147–1169, 1874. View at Google Scholar
  11. J. Zhou, J. Zhang, M. G. Lichtenheld, and G. G. Meadows, “A role for NF-κB activation in perforin expression of NK cells upon IL-2 receptor signaling,” The Journal of Immunology, vol. 169, no. 3, pp. 1319–1325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Chrul, E. Polakowska, A. Szadkowska, and J. Bodalski, “Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells,” Mediators of Inflammation, vol. 2006, Article ID 46957, 6 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Bhat and C. Watzl, “Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies,” PLoS ONE, vol. 2, no. 3, article e326, 2007. View at Publisher · View at Google Scholar
  14. T. A. Waldmann, “The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design,” Nature Reviews Immunology, vol. 6, no. 8, pp. 595–601, 2006. View at Publisher · View at Google Scholar
  15. H. G. Ljunggren and K. Malmberg, “Prospects for the use of NK cells in immunotherapy of human cancer,” Nature Reviews Immunology, vol. 7, no. 5, pp. 329–339, 2007. View at Publisher · View at Google Scholar
  16. L. Moretta, G. Pietra, E. Montaldo et al., “Human NK cells: from surface receptors to the therapy of leukemias and solid tumors,” Frontiers in Immunology, vol. 5, article 87, 2014. View at Publisher · View at Google Scholar
  17. A. Chretien, A. Le Roy, N. Vey et al., “Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity,” Frontiers in Immunology, vol. 5, p. 122, 2014. View at Publisher · View at Google Scholar
  18. B. Becknell and M. A. Caligiuri, “Natural killer cells in innate immunity and cancer,” Journal of Immunotherapy, vol. 31, no. 8, pp. 685–692, 2008. View at Publisher · View at Google Scholar
  19. T. L. Whiteside, M.-W. Sung, S. Nagashima, K. Chikamatsu, K. Okada, and N. L. Vujanovic, “Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo,” Clinical Cancer Research, vol. 4, no. 5, pp. 1135–1145, 1998. View at Google Scholar · View at Scopus
  20. T. L. Whiteside, K. Chikamatsu, S. Nagashima, and K. Okada, “Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer,” Anticancer Research, vol. 16, no. 4, pp. 2357–2364, 1996. View at Google Scholar · View at Scopus
  21. E. Alici, K. V. Konstantinidis, T. Sutlu et al., “Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model,” Experimental Hematology, vol. 35, no. 12, pp. 1839–1846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Belldegrun, C.-L. Tso, R. Kaboo et al., “Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy,” Journal of Immunotherapy, vol. 19, no. 2, pp. 149–161, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. E. L. Pearce and E. J. Pearce, “Metabolic pathways in immune cell activation and quiescence,” Immunity, vol. 38, no. 4, pp. 633–643, 2013. View at Publisher · View at Google Scholar
  24. V. A. Gerriets and J. C. Rathmell, “Metabolic pathways in T cell fate and function,” Trends in Immunology, vol. 33, no. 4, pp. 168–173, 2012. View at Publisher · View at Google Scholar
  25. K. N. Pollizzi and J. D. Powell, “Integrating canonical and metabolic signalling programmes in the regulation of T cell responses,” Nature Reviews Immunology, vol. 14, no. 7, pp. 435–446, 2014. View at Publisher · View at Google Scholar
  26. C.-H. Chang, J. D. Curtis, L. B. Maggi Jr. et al., “Posttranscriptional control of T cell effector function by aerobic glycolysis,” Cell, vol. 153, no. 6, pp. 1239–1251, 2013. View at Publisher · View at Google Scholar
  27. E. Abarca-Rojano, S. Muniz-Hernandez, M. M. Moreno-Altamirano, R. Mondragon-Flores, F. Enriquez-Rincon, and F. J. Sanchez-Garcia, “Re-organization of mitochondria at the NK cell immune synapse,” Immunology Letters, vol. 122, no. 1, pp. 18–25, 2009. View at Publisher · View at Google Scholar
  28. B. W. S. Robinson and G. Morstyn, “Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells,” Cellular Immunology, vol. 106, no. 2, pp. 215–222, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. H. L. Wieman, J. A. Wofford, and J. C. Rathmell, “Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking,” Molecular Biology of the Cell, vol. 18, no. 4, pp. 1437–1446, 2007. View at Publisher · View at Google Scholar
  30. A. Marçais, J. Cherfils-Vicini, C. Viant et al., “The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells,” Nature Immunology, vol. 15, no. 8, pp. 749–757, 2014. View at Publisher · View at Google Scholar
  31. F. Bost, A. G. Decoux-Poullot, J. F. Tanti, and S. Clavel, “Energy disruptors: rising stars in anticancer therapy?” Oncogenesis, vol. 5, no. 1, article e188, 2016. View at Publisher · View at Google Scholar
  32. L. Lai, T. C. Leone, C. Zechner et al., “Transcriptional coactivators PGC-1α and PGC-lβ control overlapping programs required for perinatal maturation of the heart,” Genes & Development, vol. 22, no. 14, pp. 1948–1961, 2008. View at Publisher · View at Google Scholar
  33. J. D. Lin, “Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism,” Molecular Endocrinology, vol. 23, no. 1, pp. 2–10, 2009. View at Publisher · View at Google Scholar
  34. C. Liu and J. D. Lin, “PGC-1 coactivators in the control of energy metabolism,” Acta Biochimica et Biophysica Sinica, vol. 43, no. 4, pp. 248–257, 2011. View at Publisher · View at Google Scholar
  35. G. López-Lluch, P. M. Irusta, P. Navas, and R. de Cabo, “Mitochondrial biogenesis and healthy aging,” Experimental Gerontology, vol. 43, no. 9, pp. 813–819, 2008. View at Publisher · View at Google Scholar
  36. B. Kupr and C. Handschin, “Complex coordination of cell plasticity by a PGC-1α-controlled transcriptional network in skeletal muscle,” Frontiers in Physiology, vol. 6, article 325, 2015. View at Publisher · View at Google Scholar
  37. J. A. Villena, “New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond,” The FEBS Journal, vol. 282, no. 4, pp. 647–672, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Basu, H. E. Broxmeyer, and G. Hangoc, “Peroxisome proliferator-activated-gamma coactivator-1alpha-mediated mitochondrial biogenesis is important for hematopoietic recovery in response to stress,” Stem Cells and Development, vol. 22, no. 11, pp. 1678–1692, 2013. View at Publisher · View at Google Scholar
  39. S. Basu, “A complex interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recovery following 5-fluorouracil treatment,” Stem Cell Research, vol. 12, no. 1, pp. 178–193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. J. S. Orange, “Formation and function of the lytic NK-cell immunological synapse,” Nature Reviews Immunology, vol. 8, no. 9, pp. 713–725, 2008. View at Publisher · View at Google Scholar
  41. J. P. Ray, M. M. Staron, J. A. Shyer et al., “The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells,” Immunity, vol. 43, no. 4, pp. 690–702, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Wu, X. Huang, Y. Feng et al., “Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells,” Proceedings of the National Academy of Sciences, vol. 103, no. 39, Article ID 16980408, pp. 14379–14384, 2006. View at Publisher · View at Google Scholar
  43. C. Ponti, D. Gibellini, F. Boin et al., “Role of CREB transcription factor in c-fos activation in natural killer cells,” European Journal of Immunology, vol. 32, no. 12, pp. 3358–3365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Di Santo, “Natural killer cell developmental pathways: a question of balance,” Annual Review of Immunology, vol. 24, no. 1, pp. 257–286, 2006. View at Publisher · View at Google Scholar
  45. A. Marçais, S. Viel, M. Grau, T. Henry, J. Marvel, and T. Walzer, “Regulation of mouse NK cell development and function by cytokines,” Frontiers in Immunology, vol. 4, article 450, 2013. View at Publisher · View at Google Scholar
  46. A. K. Ali, N. Nandagopal, and S. H. Lee, “IL-15–PI3K–AKT–mTOR: a critical pathway in the life journey of natural killer cells,” Frontiers in Immunology, vol. 6, article 355, 2015. View at Publisher · View at Google Scholar
  47. H. M. Lee, K.-S. Kim, and J. Kim, “A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta,” Cellular Immunology, vol. 290, no. 1, pp. 52–61, 2014. View at Publisher · View at Google Scholar
  48. R. Trotta, J. Dal Col, J. Yu et al., “TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells,” The Journal of Immunology, vol. 181, no. 6, pp. 3784–3792, 2008. View at Publisher · View at Google Scholar · View at Scopus